<DOC>
	<DOCNO>NCT02125474</DOCNO>
	<brief_summary>Well-differentiated neuroendocrine tumor ( WDNETs ) uncommon neoplasms increase number new case report annual statistic Instituto Nacional de Cancerología ( INC ) . The majority advanced-stage presentation limit chance complete surgical resection primary tumor , clinical scenario medical treatment option also limit . In view characteristically define expression peptide receptor WDNETs , radioactive molecular probe target specific cellular receptor design use radioisotope short range penetration tissue . We design one-arm phase II prospective sequential clinical trial ass therapeutic efficacy 177-Lu- [ DOTA 0 , Tyr 3 ] octreotate ( 177-Lu- DOTATATE ) apply intravenously three separate dos patient inoperable progressive WDNET . Selected patient match inclusion criterion enrol INC 's Section Endocrinology . Tumor response , treatment safety ( side effect ) survival appraise . Data clinical , biochemical image follow-up periodically register treatment two year last infusion 177Lu- DOTATATE . This phase II trial justify despite fact many preclinical clinical study show potential usefulness novel palliative approach treat patient advanced-stage WDNETs paucity vigorous result establish efficacy first-line treatment .</brief_summary>
	<brief_title>Efficacy 177-Lu-DOTA 0 , Tyr 3 Octreotate</brief_title>
	<detailed_description>The Investigators design one-arm phase II prospective sequential clinical trial ass therapeutic efficacy 177-Lu- [ DOTA 0 , Tyr 3 ] octreotate ( 177-Lu- DOTATATE ) apply intravenously three separate dos patient inoperable progressive WDNET .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<criteria>Patients inoperable gastroenteropancreatic neuroendocrine tumor . Histopathologic diagnosis confirm Instituto Nacional de Cancerología . Somatostatin receptorpositive tumor least one site abnormal focal uptake &gt; liver physiologic uptake ( 3+ ) observe 99mTcHYNICTOC scintigraphy practice less 6 month treatment 177Lu DOTATATE . Karnofsky functional score &gt; 60 . Life expectancy &gt; 3 month . Multiple inoperable metastatic site . Patient voluntarily willing participate trial . Hemoglobin ( Hb ) &gt; 8.8 g/dl Leucocytes ( Leu ) &gt; 2 x 103/µl Platelets ( Plaq ) &gt; 80 x 103/µl Total Bilirrubin ( BT ) ≤ 3 time upper limit normal range . Serum albumin &gt; 3 g/dl normal prothrombin time . At least one measurable CT tumor lesion . Nonlactating woman negative pregnancy blood test . Creatinine clearance &gt; 40 ml/min serum creatinine &lt; 1.5 mg/dl and/or isotopic glomerular filtration rate &gt; 50 ml/min . Test result predate treatment least : blood test result ≤ 4 week , liver blood test &lt; 1 month , renal function test &lt; 1 week , CT ≤ 4 month 99mTcHYNICTOC scintigraphy &lt; 6 month . Patients previously treat radionuclide therapy . Patients treat chemo radiotherapy within past 6 month . Patients unable comply clinical followup Nuclear Medicine Endocrinology unit . Patients unwilling participate trial provide write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Neuroendocrine Tumors</keyword>
	<keyword>Lutetium</keyword>
	<keyword>Treatment Outcome</keyword>
</DOC>